3 Reasons to Own Pfizer's Stock in 2018
Despite losing nearly $30 billion in branded pharma sales due to the loss of exclusivity for key brands like Celebrex, Lipitor, Lyrica, and Viagra over the course of 2011 to 2020, Pfizer (NYSE: PFE) remains on solid financial footing. In fact, this top pharma stock arguably sports one of the best balance sheets, dividends, and long-term growth prospects within its peer group.
Nevertheless, Pfizer's shares have lagged well behind the scorching biopharmaceutical space since 2011 due to these patent headwinds. Heading into 2018, however, I think Pfizer is now a must-own large-cap pharmaceutical stock for three clear reasons.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€25.87
-0.250%
The stock is one of the favorites of our community with 35 Buy predictions and 4 Sell predictions.
As a result the target price of 40 € shows a very positive potential of 54.62% compared to the current price of 25.87 € for Pfizer Inc..
